TVB-2640, A Novel, First-in-Class, Fatty Acid Synthase (FASN) Inhibitor: Biomarker AND Metabolomic Correlations With Clinical MRI-PDFF Response

Time: 11:30 am
day: Day 2 Stream 3 AM


• FASN inhibition decreases liver fat and markers of inflammation and fibrosis in Phase 2 NASH
• Correlation of non-invasive tests with liver fat clinical response
• Investigation of serum metabolomic markers to predict liver fat clinical response